Clinical outcome measures of psoriasis.

Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations. Here we will discuss some of the most popular clinical outcome measures of both psoriasis (Psoriasis Severity Index, Physician Global Assessment, National Psoriasis Fundation-Psoriasis Score, Dermatology Life Quality Index) and psoriatic arthritis (American College Rheumatology response criteria, Psoriatic Arthritis Response Criteria).

[1]  A. Gottlieb,et al.  The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. , 2003, Journal of drugs in dermatology : JDD.

[2]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[3]  S. Feldman,et al.  Psoriasis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[4]  D. Gladman,et al.  Assessment of patients with psoriatic arthritis: a review of currently available measures. , 2004, Arthritis and rheumatism.

[5]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[6]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[7]  R. Langley,et al.  Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. , 2004, Journal of the American Academy of Dermatology.

[8]  C. Griffiths,et al.  Quality of life measures in psoriasis: a critical appraisal of their quality , 1998, Journal of clinical pharmacy and therapeutics.

[9]  D. Reda,et al.  Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. , 1996, Arthritis and rheumatism.

[10]  S. Feldman,et al.  A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. , 2004, Journal of the American Academy of Dermatology.

[11]  G. Wells,et al.  Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? , 1998, Arthritis and rheumatism.

[12]  W. Taylor.  Assessment of outcome in psoriatic arthritis , 2004, Current opinion in rheumatology.